EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma

Xin Jin iD, Haida Shi iD, Zhi Li iD, Huixing Li iD, Huanxian Ma iD, Xianjie Shi iD

Journal of Oncology · 30.09.2022 · 2022 · 1-15

DOI: 10.1155/2022/2717056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oncology, erschienen am 30.09.2022. Verfasst von Xin Jin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA and Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of PLA General Hospital, Beijing 100853, Chi…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A large number of cancer-related deaths in the world can be attributed to liver hepatocellular carcinoma (LIHC). The purpose of this study is to explore protein tyrosine phosphatase type IV A member 3 (PTP4A3/PRL-3) as a new and reliable biomarker to predict the prognosis of LIHC and determine the potential therapeutic targets or drugs that can be used for treating LIHC.

Methods

We included three LIHC datasets with clinical information and expression profiles from public databases. The expression level of PTP4A3 was analyzed, and based on the results, the samples were divided into high- and low-expression groups. The Kaplan–Meier survival analysis method was used to determine the relationship between PTP4A3 and prognosis. The enrichment differences among the functional pathways associated with the high- and low-expression groups were determined using the gene set enrichment analysis (GSEA) method. Five methods were used to determine the differences among the tumor microenvironment in the low- and high-expression groups. The sensitivity of the low- and high-expression groups toward different drug treatment methods was predicted by analyzing the Tumor Immune Dysfunction and Exclusion (TIDE) scores and determining the biochemical half-maximal inhibitory concentration (IC50).

Results

The expression levels of the LIHC and adjacent samples were analyzed, and it was observed that the expression level of PTP4A3 in tumor tissue was significantly higher than the expression level of the same gene in the adjacent samples. It was also inferred that it might be a cancer-promoting gene. It was concluded that high-expression results in a significantly poor prognosis. The high-expression group was significantly enriched in the tumor-related pathways, such as the PI3K-AKT signaling pathway. In addition, the results obtained by conducting immune infiltration analysis revealed a significant positive correlation between some immune scores and the gene PTP4A3. The drug KIN001−135 and gene PTP4A3 were also found to correlate positively with each other. CP466722, Pyrimethamine, AKT inhibitor VIII, Embelin, Cisplatin, QS11, Bexarotene, and Midostaurin negatively correlated with PTP4A3 associated with the three datasets. Moreover, the drugs Cisplatin, QS11, Midostaurin, and CP466722 were more sensitive toward the high-expression group than the low PTP4A3 expression group. Significant differences were observed in these cases.

Conclusion

PTP4A3/PRL-3 is potentially associated with the progression, metastasis, and invasion of LIHC. The prognosis of LIHC patients is negatively impacted by the high-expression levels of the gene. The results indicate that PTP4A3/PRL-3 is an important prognostic factor for LIHC and is a new potential prognostic detection target. The discovery of the 8 drugs that were negatively associated with PTP4A3 provided a new direction that can be developed in the future for the treatment of LIHC.

Autor:innen und Institutionen

  • Medical School of Chinese PLA and Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of PLA General Hospital, Beijing 100853, China.
  • Emergency Department of the Fourth Medical Center of PLA General Hospital, Beijing 100853, China.
  • Department of General Surgery, General Hospital of Eastern Theater Command, Nanjing 210002, China.
  • Department of Hepatobiliary Surgery, Aerospace Center Hospital, Beijing 100049, China.
  • Department of Critical Care Medicine, Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of PLA General Hospital, Beijing 100853, China.
  • Medical School of Chinese PLA and Department of Hepatobiliary and Pancreatic Surgery, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518033, China.

ORCID-Profile: Xin Jin, Haida Shi, Zhi Li, Huixing Li, Huanxian Ma, Xianjie Shi

Zitieren

APA

Jin, X., Shi, H., Li, Z., Li, H., Ma, H., & Shi, X. (2022). Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma. Journal of Oncology, 2022, 1-15. https://doi.org/10.1155/2022/2717056

Vancouver

Jin X, Shi H, Li Z, Li H, Ma H, Shi X. Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma. Journal of Oncology. 2022;2022:1-15. doi:10.1155/2022/2717056

BibTeX
@article{Jin2022,
  author = {Jin, Xin and Shi, Haida and Li, Zhi and Li, Huixing and Ma, Huanxian and Shi, Xianjie},
  title = {Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma},
  journal = {Journal of Oncology},
  year = {2022},
  volume = {2022},
  pages = {1--15},
  doi = {10.1155/2022/2717056}
}
Kostenlos starten →